Journalartikel
Autorenliste: Pullamsetti, Soni Savai; Schermuly, Ralph; Ghofrani, Ardeschir; Weissmann, Norbert; Grimminger, Friedrich; Seeger, Werner
Jahr der Veröffentlichung: 2014
Seiten: 394-400
Zeitschrift: American Journal of Respiratory and Critical Care Medicine
Bandnummer: 189
Heftnummer: 4
ISSN: 1073-449X
eISSN: 1535-4970
DOI Link: https://doi.org/10.1164/rccm.201308-1543PP
Verlag: American Thoracic Society
Abstract:
The development of therapeutic concepts in pulmonary hypertension (PH) is intimately linked with the unraveling of pathogenetic sequelae. This perspective highlights advances in our understanding of the regulation of vasomotion and vascular remodeling that have led to "reverse-remodeling" and regenerative strategies as novel treatment concepts. Progress has been made in understanding redox-dependent signaling; inflammatory sequelae; and transcription factor, ion channel, and metabolic abnormalities, as well as growth factor-dependent hyperproliferation that underlies PH. We are, however, far from understanding the molecular pathways that differentially drive the various vascular phenotypes (intimal thickening, media hypertrophy, adventitial thickening, strategies, transcription factor-based therapies, inflammation/immune cell-focused approaches, and epigenetic modulation-based therapies are all novel treatment concepts for PH. The proangiogenic potential of genetically engineered mesenchymal stem cells and endothelial progenitor cells has been explored as a regenerative strategy. The progress that has been made in identifying important cellular and molecular mechanisms and applying this knowledge to novel therapies is largely restricted to group 1 PH. However, understanding the molecular sequelae underlying PH in groups 2 through 5 PH is also urgently needed.
Zitierstile
Harvard-Zitierstil: Pullamsetti, S., Schermuly, R., Ghofrani, A., Weissmann, N., Grimminger, F. and Seeger, W. (2014) Novel and Emerging Therapies for Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, 189(4), pp. 394-400. https://doi.org/10.1164/rccm.201308-1543PP
APA-Zitierstil: Pullamsetti, S., Schermuly, R., Ghofrani, A., Weissmann, N., Grimminger, F., & Seeger, W. (2014). Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 189(4), 394-400. https://doi.org/10.1164/rccm.201308-1543PP
Schlagwörter
ARTERIAL-HYPERTENSION; molecular mechanisms; Pulmonary hypertension; regenerative strategies; SORAFENIB; vascular remodeling; VASOCONSTRICTION
